$Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)$

Phase II study of lenvatinib for metastatic colorectal cancer refractory to standard chemotherapy: the LEMON study (NCCH1503)

BackgroundLenvatinib inhibits tyrosine kinases, including vascular endothelial growth factor (VEGF) receptor, fibroblast growth factor receptor, platelet-derived growth factor receptor alpha, RET proto-oncogene and KIT proto-oncogene, receptor tyrosine kinase. We assessed the efficacy and safety of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	ESMO open 2020-08, Vol.5 (4), p.e000776, Article e000776
Hauptverfasser:	Iwasa, Satoru, Okita, Natsuko, Kuchiba, Aya, Ogawa, Gakuto, Kawasaki, Mamiko, Nakamura, Kenichi, Shoji, Hirokazu, Honma, Yoshitaka, Takashima, Atsuo, Kato, Ken, Hamaguchi, Tetsuya, Boku, Narikazu, Yamada, Yasuhide
Format:	Artikel
Sprache:	eng
Schlagworte:	Adult Aged colorectal cancer Colorectal Neoplasms - drug therapy Female Humans lenvatinib Male Middle Aged Neoplasm Metastasis Original Research phase 2 Phenylurea Compounds - therapeutic use Proto-Oncogene Mas Quinolines - therapeutic use salvage-line Vascular Endothelial Growth Factor A
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!